Created at 4:51 p.m. Feb, 02, 2025
Author: lesdon
Related Note: 1488765251203 2
Rationale for change

it could be interpreted as a ratio of PR to INR

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::01_Warfarin #AK_Step2_v12::!Shelf::EM #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::03_Warfarin #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::02_Secondary_Hemostasis #AK_Step1_v12::#UWorld::Step::1200 #AK_Step2_v12::Original_decks::Dorian::im::ome::heme/onc::bleeding #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::03_Heparin_vs_warfarin::*Warfarin #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::02_Warfarin #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::02_Coagulopathy #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation #AK_Step1_v12::#NBME::22 #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::07_Anticoagulant_Drugs #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#UWorld::COMLEX::24311 #AK_Step2_v12::#SketchyIM::01_Cardiology::05_Blood_Vessel_Disease::01_DVT_SOAP #AK_Step1_v12::#Pixorize::01_Biochemistry::21_Lab_Diagrams::03_Coagulation_Panel #AK_Step2_v12::#Bootcamp::Medicine::01_Cardiology::02_Valvular_Disease::10_Prosthetic_Heart_Valves #AK_Step2_v12::#OME::01_Medicine::05_Hematology_Oncology::08_Bleeding #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::03_Physiology::05_Coagulation_and_kinin_pathways::*Coagulation_Cascade #AK_Step1_v12::#AMBOSS::M5aMkO #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_Hematology #AK_Step1_v12::#Bootcamp::Biochemistry::12_Vitamins::06_Vitamin_K_Clinical_Implications #AK_Step2_v12::#SketchyIM::02_ECG_Interpretation_&_Arrhythmias::04_Tachycardia::04_Narrow_Complex_Tachycardia:_AFib_&_AFlutter_Management #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#Pixorize::01_Biochemistry::17_Coagulation::02_Extrinsic_Pathway_of_Coagulation #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step1_v12::#Pathoma::04_Hemostasis::02_Secondary_Hemostasis_&_Related_Disorders #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::02_Bleeding_Time,_Prothrombin_Time,_INR,_and_Partial_Thromboplastin_Time #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step2_v12::#Resources_by_rotation::IM::ome::heme/onc::bleeding #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::01_Bleeding_&_Clotting_Disorders::01_Bleeding_Disorders:_Coagulation_Factor_Disorders_DDx #AK_Step2_v12::#SketchySurgery::02_Trauma,_Burns,_Critical_Care::03_Abdominal_Trauma::01_Hemorrhage_and_Hypovolemic_Shock #AK_Step1_v12::#AMBOSS::lQavw4 #AK_Step2_v12::#AMBOSS #AK_Step1_v12::^Systems::HemeOnc::Hematology #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::09_Vitamin_K_Dependent_Coagulation_Factors #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::02_Warfarin #AK_Step1_v12::#AMBOSS #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::03_Antiplatelet,_Anticoagulant,_Thrombolytic_Agents